Peter Kyle
DSIT
9 July 2024NewsEuropeMuireann Bolger

Labour govt appoints new Minister with IP oversight

New Secretary of State previously vowed Labour would harness AI and "put it to work for everyone from every background” | Starmer’s government expected to adopt a tougher position on AI regulation and laws | Proposed regulatory innovation office would expedite decisions for “fast, clear and consistent regulation”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
1 February 2022   UK politicians are proposing that the country waive UK registered IP related to vaccines and treatments in the event of a pandemic.
Biotechnology
30 January 2024   MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More on this story

Big Pharma
1 February 2022   UK politicians are proposing that the country waive UK registered IP related to vaccines and treatments in the event of a pandemic.
Biotechnology
30 January 2024   MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More on this story

Big Pharma
1 February 2022   UK politicians are proposing that the country waive UK registered IP related to vaccines and treatments in the event of a pandemic.
Biotechnology
30 January 2024   MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.